Agents affecting the digestive system and metabolism
| Name | Dosage form | ATC code |
|---|---|---|
|
Alpha-tocopherol acetate (vitamin E) Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
50 mg/ml, 20 ml № 1 | A11HA03 |
|
Alpha-tocopherol acetate (vitamin E) Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
100 mg/ml, 20 ml № 1 | A11HA03 |
|
Alpha-tocopherol acetate (vitamin E) Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
300 mg/ml, 20 ml № 1 | A11HA03 |
|
Aquavit-D3 Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
375 mcg/ml, 10 ml № 1 | A11CC05 |
![]() Ascorbic acid Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
25 mg №50 | A11GA01 |
|
Ascorbic acid Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
25 mg № 100 | A11GA01 |
|
Ascorbic acid Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
50 mg № 50 | A11GA01 |
|
Ascorbic acid Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
50 mg/ml, 2 ml № 10, № 100 | A11GA01 |
|
Ascorbic acid Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
100 mg/ml, 2 ml № 10, № 100 | A11GA01 |
![]() Bisacodyl Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
0,01 g № 10 | A06AB02 |
![]() Carbacid Pechaevskiy Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№ 20 | A02AX |
![]() Dalmaxin Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
0,2 g № 5, № 10 | A05BA |
![]() Ergocalciferol (vitamin D2) Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
0,125 %, 10 ml № 1 | A11CC01 |
![]() Glibenclamide Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
5 mg № 30 | А10ВВ01 |
![]() Heksavit Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№ 50 | A11BA |
|
Kreazim 10000 Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№ 20 | A09AA02 |
![]() Kreazim 20000 Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№ 20 | A09AA02 |
|
|
2 ml № 5 | А11DВ |
![]() Leksadyl Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
10 mg № 10 | А06АВ02 |
![]() Lektac Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
150 mg № 10, № 20, № 30 | A02BA02 |
![]() Loperamide Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
0,002 g № 10, № 20 | A07DA03 |
|
Methovitan Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
20 hard capsules | А11АВ |
![]() Methyluracil Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
0,5 g, № 5 ,№ 10 | A14B |
![]() Nevrolek Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
2 ml № 5 | A11DB |
![]() No-H-Sha Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
0,04 g № 10 | A03AD02 |
![]() No-H-Sha Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
0,04 g № 10, № 30 | A03A D02 |
![]() No-H-Sha Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
20 mg/mg, 2 ml in ampoules № 5 | A03AD02 |
![]() No-H-Sha forte Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
0,08 g № 30 | A03AD02 |
![]() Ondansetron Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
2 mg/ml 4 ml № 5 | A04AA01 |
![]() Ondansetron Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
4 mg № 10 | A04AA01 |
![]() Ondansetron Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
8 mg № 10 | A04AA01 |
![]() Ondansetron Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
2 mg/ml 2 ml № 5 | A04AA01 |
|
Pancreatin 8000 Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№ 20, №50 | A09AA02 |
![]() Pancreazim Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№ 20, № 50 | A09AA02 |
![]() Pancreazim 10000 Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№ 20, № 50 | А09АА02 |
![]() Pancreazim 10000 Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№ 20, № 50 | А09АА02 |
![]() Papaverine Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
20 mg/ml, 2 ml № 10 | A03AD01 |
![]() Pyridoxine hydrochloride (vitamin В6) Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
50 mg/ml, 1 ml № 10 | A11HA02 |
![]() Ranitidine Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
150 mg №30 | A02BA02 |
![]() Ranitidine Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
150 mg № 20 | A02BA02 |
![]() Renalgan Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№20 | A03DA02 |
![]() Renalgan Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
5 ml №5 | A03DA02 |
![]() Renalgan Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№ 10 | A03DA02 |
![]() Renalgan Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
2 ml №10 | A03DA02 |
![]() Retinol acetate (vitamin A) Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
34,4 mg/ml, 10 ml № 1 | A11CA01 |
![]() Revit Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№ 75, № 100 | A11BA |
![]() Solizym forte Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
№ 20 | A09AA |
![]() Stomolik Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
125 ml № 1 | А01АВ12 |
![]() Thiamine chloride (vitamin В1) Active ingredient
Pharmacotherapeutic group Agents affecting the digestive system and metabolism |
50 mg/ml, 1 ml in ampoules № 10 | A11DA01 |
Agents affecting blood system and hemapoiesis
| Name | Dosage form | ATC code |
|---|---|---|
|
Aquaferrol Active ingredient
Pharmacotherapeutic group Agents affecting blood system and hemapoiesis |
10 mg/ml, 125 ml № 1 | В03АВ05 |
![]() Cyanocobalamin (vitamin В12) Active ingredient
Pharmacotherapeutic group Agents affecting blood system and hemapoiesis |
0,5 mg/ml, 1 ml № 10 | B03BA01 |
![]() Ferrofol Active ingredient
Pharmacotherapeutic group Agents affecting blood system and hemapoiesis |
№ 30 | В03АD04 |
![]() Folic acid Active ingredient
Pharmacotherapeutic group Agents affecting blood system and hemapoiesis |
5 mg № 50 | B03BB01 |
![]() Folic acid Active ingredient
Pharmacotherapeutic group Agents affecting blood system and hemapoiesis |
1 mg № 50 | B03BB01 |
![]() Magnesium sulfate Active ingredient
Pharmacotherapeutic group Agents affecting blood system and hemapoiesis |
250 mg/ml, 5 ml № 10 | B05XA05 |
![]() Sodium chloride Active ingredient
Pharmacotherapeutic group Agents affecting blood system and hemapoiesis |
9 mg/ml, 5 ml №10 | B05XA03 |
![]() Tranexamic acid Active ingredient
Pharmacotherapeutic group Agents affecting blood system and hemapoiesis |
50 mg/ml, 5 ml № 5, № 10, № 100 | B02AA02 |
![]() Tranexamic acid Active ingredient
Pharmacotherapeutic group Agents affecting blood system and hemapoiesis |
100 mg/ml, 5 ml № 5, № 10, № 100 | B02AA02 |
![]() Trombolik-Cardio Active ingredient
Pharmacotherapeutic group Agents affecting blood system and hemapoiesis |
100 mg № 20 | B01AC06 |
Agents affecting cardio-vascular system
| Name | Dosage form | ATC code |
|---|---|---|
![]() Accordin Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
100 mg/ml, 5 ml № 5, № 10, № 100 | С01ЕВ22 |
|
Amiodarone Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
0,2 g № 30 | C01BD01 |
![]() Amlodipine 10 Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
10 мг №30 | С08С А01 |
![]() Amlodipine 10 Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
10 mg №60 | С08С А01 |
![]() Amlodipine 10 Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
10 mg №90 | С08С А01 |
![]() Amlodipine 5 Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
5 mg №30 | С08С А01 |
![]() Amlodipine 5 Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
5 mg №60 | С08С А01 |
![]() Amlodipine 5 Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
5 mg №90 | С08С А01 |
|
Anaesthesolum Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
№ 5, № 10 | C05AD |
|
Ascorutin Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
№ 50, № 800 | C05CA51 |
|
Beladonna Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
0,015 g № 10 | C05AX |
|
|
№ 10 | C05AX03 |
![]() Enalapril Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
0,01 g № 20 | C09AA02 |
![]() Enalapril Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
0,01 g № 90 | C09AA02 |
![]() Enalapril Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
0,01 g № 50 | C09AA02 |
![]() Larginus Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
100 мл | С01E |
|
|
15 mg № 10 | C05AX |
|
|
№ 5, № 10 | C05AD |
![]() Nicotinic acid Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
50 mg № 50 | C04AC01 |
![]() Nifedipine Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
20 mg № 50 | C08CA05 |
![]() Nifedipine Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
10 mg № 50 | C08CA05 |
![]() Nitroglycerine Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
0,5 mg № 40 | C01DA02 |
![]() Nitrogranulong Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
5,2 mg № 10, № 50 | C01DA02 |
![]() Nitrogranulong Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
2,9 mg № 10, № 50 | C01DA02 |
![]() Oftalek Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
10 mg/ml 1 ml №10 | С05СX |
![]() Pentoxifylline Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
100 mg № 10, № 50 | C04AD03 |
![]() Propolis Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
0,1 g № 5, № 10 | C05AX |
![]() Riboxin Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
200 mg № 10, № 50 | C01EB |
![]() Spironolactone Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
25 mg №20 | C03D A01 |
![]() Spironolactone Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
50 mg №20 | C03D A01 |
![]() Spironolactone Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
100 mg №20 | C03D A01 |
![]() Spironolactone Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
25 mg №50 | C03D A01 |
![]() Spironolactone Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
50 mg №50 | C03D A01 |
![]() Spironolactone Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
100 mg №50 | C03D A01 |
![]() Spironolactone Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
100 mg №30 | C03D A01 |
![]() Spironolactone Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
50 mg №30 | C03D A01 |
![]() Spironolactone Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
25 mg №30 | C03D A01 |
![]() Torasemide Active ingredient
Pharmacotherapeutic group Agents affecting cardio-vascular system |
5 mg/ml 2 ml, 4 ml № 5, № 10, № 100 | C03CA04 |
Dermatological agents
| Name | Dosage form | ATC code |
|---|---|---|
|
|
50 ml № 1 | D03AX |
|
|
50 ml, 100 ml | D03АX |
|
|
100 ml № 1 | D03AX |
|
|
10 % 30 ml № 1 | D08AG02 |
|
|
10 % 120 ml № 1 | D08AG02 |
|
|
10 % 1000 ml № 1 | D08AG02 |
|
|
10 ml № 1 | D01AE22 |
Agents affecting genitourinary system and reproductive hormones
| Name | Dosage form | ATC code |
|---|---|---|
![]() Chinofucin Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
0,015 g № 5, № 10 | G01AC03 |
![]() Eucolec Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
0,05 g № 5, № 10 | G01AX |
![]() Klioron Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
16 mg № 10 | G01AX |
![]() Klioron V Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
16 mg № 10 | G01AX |
![]() Lekfucin Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
15 mg № 5, № 10 | G01AС03 |
![]() Leknazole Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
150 mg № 3 | G01АF05 |
![]() Lekvolek Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
50 mg № 5, № 10 | G01AX |
![]() Levoklek Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
50 mg № 5, № 10 | G01AX |
![]() Omix Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
0.4 mg № 10, № 30 | G04C A02 |
![]() Omix Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
0,4 mg № 10, № 30 | G04CA02 |
![]() Potentiale Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
50 mg № 2 | G04BE03 |
![]() Potentiale Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
50 mg №4 | G04BE03 |
![]() Potentiale Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
100 mg №2 | G04BE03 |
![]() Potentiale Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
100 mg №4 | G04BE03 |
![]() Potentiale Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
100 mg № 1 | G04BE03 |
![]() Potentiale Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
50 mg № 1 | G04BE03 |
![]() Povidin Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
0,3 g № 5, № 10 | G01AX11 |
![]() Prostan Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
5 mg № 10, № 30 | G04CB01 |
![]() Prostatilen Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
0,03 g №5 | G04CX |
![]() Prostatilen Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
0,03 g № 10 | G04CX |
![]() Prostatilen Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
2 ml № 5, № 10 | G04СX |
![]() Prostatilen-Zinc Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
№10 | G04CX |
![]() Prostatilen-Zinc Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
№ 5 | G04CX |
![]() Santekvin Active ingredient
Pharmacotherapeutic group Agents affecting genitourinary system and reproductive hormones |
0,15 g № 3 | G01AF05 |
Hormone drugs for systemic use
| Name | Dosage form | ATC code |
|---|---|---|
![]() Bemedozon Active ingredient
Pharmacotherapeutic group Hormone drugs for systemic use |
4 mg/ml, 1 ml № 5, № 10, № 100 | Н02АВ01 |
![]() Dexamethasone Active ingredient
Pharmacotherapeutic group Hormone drugs for systemic use |
4 mg/ml, 1 ml № 5 | H02AB02 |
![]() Lekthasone Active ingredient
Pharmacotherapeutic group Hormone drugs for systemic use |
4 mg/1 ml № 5, № 100 | H02AB02 |
Antimicrobial agents for systemic use
| Name | Dosage form | ATC code |
|---|---|---|
|
Aciclovir Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
0,2 g № 10, № 20 | J05AB01 |
|
Amicacin sulfate Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
50 mg/ml, 2 ml № 1 | J01GB06 |
![]() Amikacin sulfate Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
250 mg/ml, 4 ml № 1 | J01GB06 |
|
Amikacin sulfate Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
250 mg/ml, 2 ml № 1 | J01GB06 |
|
|
1,0 g № 5 | J01DB04 |
|
|
1,0 g № 1 | J01DB04 |
![]() Cefazolin 1000 Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g № 5 | J01DB04 |
![]() Cefazolin 1000 Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g № 1 | J01DB04 |
![]() Cefazolin combi Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
0,5 g № 1, № 10, № 50 | J01DB04 |
|
|
1 g № 1 | J01DE01 |
![]() Cefepime with solvent Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 г № 1 | J01DE01 |
![]() Cefotaxime Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g № 5 | J01DD01 |
![]() Cefotaxime Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g № 1 | J01DD01 |
![]() Cefotaxime Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g № 50 | J01DD01 |
![]() Cefotaxime Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g № 5 | J01DD01 |
![]() Cefotaxime Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g № 1 | J01DD01 |
![]() Cefotaxime + Water for injection Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1 vial and 1 ampoule | J01D D01 |
![]() Cefotaxime combi Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
0,5 g №1 | J01DD01 |
![]() Ceftazidime Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g № 1, № 5, № 50 | J01DD02 |
![]() Ceftriaxone Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g № 5 | J01DD04 |
![]() Ceftriaxone Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g №1 | J01DD04 |
![]() Ceftriaxone Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g №5 | J01DD04 |
![]() Ceftriaxone Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g №50 | J01DD04 |
![]() Ceftriaxone Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g №50 | J01DD04 |
|
Ceftriaxone Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g № 1 | J01DD04 |
![]() Ceftriaxone + Lidocaine Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1 vial and 1 ampoule | J01D D04 |
![]() Ceftriaxone + Water for injection Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1 vial and 1 ampoule | J01D D04 |
![]() Ceftriaxone 500 Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
0,5 g № 1, № 10, № 50 | J01D D04 |
![]() Cefuroxime Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
0,75 g №1 | J01DC02 |
![]() Cefuroxime Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
0,75 g №1 | J01DC02 |
![]() Cefuroxime Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,5 g №1 | J01DC02 |
![]() Cefuroxime Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,5 g № 1 | J01DС02 |
![]() Cefuroxime + Water for injection Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1 vial and 1 ampoule | J01D С02 |
![]() Cilpen Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
500 mg/500 mg № 10 | J01DH51 |
![]() Cilpen Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
500 mg/500 mg № 1 | J01DH51 |
![]() Ciprofloxacin Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
500 mg № 10 | J01MA02 |
![]() Ciprofloxacin Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
250 mg № 10 | J01MA02 |
![]() Cycloserine Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
250 mg № 30 | J04AВ01 |
![]() Fluconazole Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
150 mg №2 | J02AC01 |
![]() Fluconazole Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
50 mg № 10 | J02AC02 |
![]() Fluconazole Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
100 mg № 10 | J02AC01 |
![]() Fluconazole Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
150 mg № 1 | J02AC01 |
![]() Lamivudine Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
150 mg № 60 | J05AF05 |
![]() Lamivudine Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
10 mg/ml, 240 ml № 1 | J05А F05 |
|
|
№ 60 | J05AR01 |
![]() Lekcef + water for injections Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1 vial and 1 ampoule | J01DD04 |
![]() Lekcef + Water for injections Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1 vial and 1 ampoule | J01DD04 |
|
|
200 mg № 10 | J01MA01 |
|
|
1,0 g № 1 | J01DB04 |
|
|
1.0 g № 1 | J01DD01 |
![]() Lektaxime + Water for injection Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1 vial and 1 ampoule | J01DD01 |
![]() Levofloxacin Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
250 mg № 10 | J01MA12 |
![]() Levofloxacin Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
500 mg № 10 | J01MA12 |
|
|
1,0 g №1 | J01DH02 |
|
|
1,0 g № 1 | J01DH02 |
![]() Moxifloxacin Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
400 мг №7 | J01MA14 |
![]() Moxifloxacin Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
400 mg №10 | J01MA14 |
![]() Moxifloxacin Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
400 mg №5 | J01MA14 |
![]() Nitroxoline Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
50 mg № 10, № 50 | J01XX07 |
![]() Ofloxacin Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
0,2 g № 10 | J01MA01 |
![]() Promocef Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
1,0 g № 1, № 5 | J01DD04 |
![]() Protech Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
250 mg № 50, № 500 | J04AD01 |
![]() Sodium aminosalicylate Pharmacotherapeutic group Antimicrobial agents for systemic use |
0,8 g/1g, 100 g № 1 | J04AA02 |
![]() Terizidone Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
250 mg № 10 | J04AK03 |
![]() Triseptol Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
100 mg/20 mg № 20 | J01EE01 |
![]() Triseptol Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
400 mg/80 mg № 20 | J01EE01 |
|
|
0,2 g № 10 | J01MB04 |
![]() Zidovudine Active ingredient
Pharmacotherapeutic group Antimicrobial agents for systemic use |
10 mg/ml 200 ml | J05AF01 |
Agents affecting musculo-skeletal system
| Name | Dosage form | ATC code |
|---|---|---|
![]() Blockpain Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
30 mg/ml, 1 ml №10 | M01AB15 |
|
Desket Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
25 mg/ml, 2 ml № 10 | M01AE17 |
![]() Diclofenac Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
0,1 g № 10 | M01AB05 |
![]() Diclofenac Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
25 mg/ml, 3 ml №5 | M01AB05 |
![]() Ibuprofen Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
200 mg № 50 | M01AE01 |
![]() Ibuprofen 200 Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
200 mg № 10, № 50, № 900 | М01А Е01 |
![]() Ibuprofen 200 Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
200 mg №50 | M01AE01 |
![]() Ibuprofen 400 Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
400 mg № 10, №20, № 50 | M01A E01 |
![]() Ibuprofen 400 Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
400 mg № 50 | М01АЕ01 |
![]() Ibuprofen 400 Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
400 mg №10 | М01АЕ01 |
![]() Ibuprofen 400 Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
400 mg №20 | М01АЕ01 |
![]() Inflamine Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
15 mg/1,5 ml in ampoule № 5 | М01АС06 |
![]() Inflamine Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
0,015 g № 10 | M01AC06 |
![]() Ketalgin Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
0,01 g, № 10 | M01AB15 |
|
|
100 mg № 10 | M01AB05 |
![]() Lekfenac Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
75 mg/3 ml № 5, № 100 | М01АВ05 |
![]() Lektalgin Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
30 mg/ml 1 ml № 10, № 100 | M01AB15 |
![]() Meloxicam Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
0,0075 g № 10 ,№ 20 | M01AC06 |
![]() Meloxicam Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
0,015 g № 10, № 20 | M01AC06 |
![]() Nimesulide Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
0,1 g № 10, № 30 | M01AX17 |
![]() Ortophen Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
25 mg № 10, № 30 | M01AB05 |
![]() Zoledronic acid Active ingredient
Pharmacotherapeutic group Agents affecting musculo-skeletal system |
0,8 mg/ml, 5 ml № 1, № 5, № 10 | М05ВА08 |
Agents affecting the nervous system
| Name | Dosage form | ATC code |
|---|---|---|
|
Acetylsalicylic acid Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
500 mg № 10 | N02BA01 |
|
Alzhmerat Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
250 mg/ml, 4 ml № 5 | N07AX02 |
![]() Alzhmerat Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
600 mg/7 ml № 10 | N07A X02 |
|
Amitriptylline Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
25 mg № 50, № 1000 | N06AA09 |
|
Analgin Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
500 mg/ml, 2 ml № 10 | N02BB02 |
|
Analgin for children Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
0,1 g № 10 | N02BB02 |
|
Analgin for children Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
0,25 g № 10 | N02BB02 |
|
|
100 mg №50 | N05AH02 |
|
|
25 mg № 50 | N05AH02 |
|
Barviton Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
5 mg/ml, 2 ml № 10 | N06BX18 |
![]() Carbamazepine Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
200 mg №20 | N03AF01 |
![]() Carbamazepine Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
200 mg № 50 | N03AF01 |
![]() Cilityn Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
250 mg/ml, 4 ml № 5, № 10, № 100 | N06BX06 |
![]() Cinnarizine Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
0,025 g № 25, № 50 | N07CA02 |
![]() Cylityne Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
100 mg, 30 ml | N06BX06 |
|
|
300 mg №100 | N03AX12 |
|
|
300 mg № 20 | N03AX12 |
![]() Ipidacord Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
15 mg/ml 1 ml №10 | N07АА |
![]() Ipidacord Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
5 mg/ml 1 ml №10, №100 | N07АА |
|
|
75 мг №21 | N03A X16 |
|
|
150 мг №21 | N03A X16 |
|
|
300 мг №21 | N03A X16 |
|
|
75 mg №56 | N03A X16 |
|
|
150 mg №56 | N03A X16 |
|
|
300 mg №56 | N03A X16 |
![]() Leknizine Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
0,025 g № 10, № 50 | N07CA02 |
|
|
200 mg №50 | N03A F01 |
![]() Lidocaine Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
10 mg/ml, 3,5 ml № 10 | N01BВ02 |
![]() Lidocaine Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
20 mg/ml, 2 ml in ampoules № 10 | N01BB02 |
![]() Nalbuphine Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
10 mg/ml 1 ml №10 | N02AF02 |
![]() Nalbuphine Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
10 mg/ml 2 ml №5 | N02AF02 |
![]() Novocaine Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
5 mg/ml, 5 ml № 10 | N01BA02 |
![]() Paracetamol Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
500 mg №10, №20, №50 | N02B E01 |
![]() Piracetam Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
200 mg/mg, 5 ml № 10 | N06BX03 |
![]() Tet 36.6 RAPID with acacia flavour Pharmacotherapeutic group Agents affecting the nervous system |
23 g № 5, № 10 | N02BЕ51 |
![]() Tet 36.6 RAPID with lemon flavour Pharmacotherapeutic group Agents affecting the nervous system |
23 g № 5, № 10 | N02BЕ51 |
![]() Tеt 36.6 MAXI with lemon flavour Pharmacotherapeutic group Agents affecting the nervous system |
23 g № 5, № 10 | N02BЕ51 |
![]() Tеt 36.6 MAXI with raspberry flavour Pharmacotherapeutic group Agents affecting the nervous system |
23 g № 5, № 10 | N02BE51 |
![]() Tеt 36.6 with acacia flavour Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
13,1 g № 5, № 10 | N02BE51 |
|
Venocor Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
50 mg/ml 2 ml № 10 | N07XX |
|
Venocor Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
50 mg/ml, 5 ml № 5 | N07XX |
![]() Vinpocetin Active ingredient
Pharmacotherapeutic group Agents affecting the nervous system |
0,005 g № 30, № 50 | N06BX18 |
Anti-parasite agents, insecticides and repellents
| Name | Dosage form | ATC code |
|---|---|---|
![]() PerMin Active ingredient
Pharmacotherapeutic group Anti-parasite agents, insecticides and repellents |
50 g | - |
![]() PerMin NEW Active ingredient
Pharmacotherapeutic group Anti-parasite agents, insecticides and repellents |
50 ml | - |
Agents affecting the respiratory system
| Name | Dosage form | ATC code |
|---|---|---|
![]() Alergolik Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
5 mg № 30 | R06AE09 |
|
Alergolik Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
5 mg № 10 | R06AE09 |
|
Alergolik Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
5 mg/ml, 10 ml № 1 | R06AE09 |
|
Ambroxol Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
0,03 g № 20 | R05CB06 |
![]() Desloratadine Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
0,5 mg/ml, 60 ml № 1 | R06AX27 |
![]() Desloratadine Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
5 mg № 10, № 30 | R06AX27 |
![]() Ketotifen Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
0,001 g № 30 | R06AX17 |
![]() Ketotifen Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
0,001 g № 10 | R06AX17 |
![]() Loratadine Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
0,01 g № 10 | R06AX13 |
![]() Loratadine Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
0,01 g № 20 | R06AX13 |
|
|
50 ml | R02AA20 |
|
|
125 ml | R02AA20 |
![]() Mucolik Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
2%, 125 ml | R05CB03 |
![]() Mucolik Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
5%, 125 ml | R05СВ03 |
![]() Mucosol Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
7,5 мг/мл 2 ml №5 | R05CB06 |
![]() Mucosol Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
7,5 мг/мл 2 ml №10 | R05C B06 |
![]() Suprostilin Active ingredient
Pharmacotherapeutic group Agents affecting the respiratory system |
0,025 g № 10, № 20 | R06AC03 |
Miscellaneous agents
| Name | Dosage form | ATC code |
|---|---|---|
|
|
10 mg/ml 5 ml № 5 | V03AF03 |
|
|
2 ml № 10 | V07AB |
|
|
5 ml № 10 | V07AB |
| Name | Dosage form | ATC code |
|---|---|---|
|
|
500 ml, 1000 ml, 5000 ml | |
|
|
50 ml | |
|
|
1000 mg №60 | - |
|
|
50 mg №200 | - |
|
|
№ 5, № 10 | - |
|
|
№ 5, № 10 | - |
|
|
100 ml | - |
|
|
№ 5, № 10 | - |
|
|
10 ml, 100 ml | - |
|
|
1,4 g № 10 | |
|
|
№50 | - |
|
|
№50 | - |
|
|
50 tablets, 0,1 g | - |
|
|
№ 10, № 14 | - |
|
|
with raspberry taste | - |
|
|
with mint taste | - |
|
|
with forest berry taste | - |
|
|
with tangerine taste | - |
|
|
with no-sugar contains | - |













































































































































































































































































